Annovis Bio, Inc., has completed a two-part Phase 2a study of ANVS401 (also known as Posiphen), its investigational treatment for Alzheimer’s and Parkinson’s disease. ANVS401 works by inhibiting the formation of beta-amyloid and tau in Alzheimer’s and alpha-synuclein in Parkinson’s, which differs from other drugs that aim to clear these compounds after they’ve formed.
There are currently no treatments available for multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder caused by the accumulation of alpha-synuclein in the brain. MSA causes problems with movement, balance, and the control of some involuntary bodily functions such as blood pressure and bowel and bladder function. Last month, Alterity Therapeutics published promising results in Movement Disorders of ATH434 in a mouse model of the disease.
Specialized neurologic and neurosurgical care center Marcus Neuroscience Institute, part of Baptist Health South Florida, is now offering its patients the Syn-One Test. Sameea Husain Wilson, D.O., director of Movement Disorder Neurology for the institute, cites the simplicity of administering the test, its high level of accuracy, and the speed with which patients get results as the major benefits of the test.
Biopharmaceutical company Seelos Therapeutics in conjunction with researchers at Duke University School of Medicine announced promising results for an epigenome-editing therapy designed to reduce alpha-synuclein levels.
News came last week that after the controversial early-June approval of Aduhelm, the first new treatment for Alzheimer’s disease in almost 20 years, the FDA (at manufacturer Biogen’s request) had narrowed its recommendation of who should receive it.
Aducanumab, the first treatment for Alzheimer’s disease to be approved in nearly two decades, has generated a fair share of interest—and controversy—since it was given approval by the FDA on June 7
Dr. Todd Levine, Co-Founder and Chief Medical Officer of CND Life Sciences made his podcast debut last week when he sat down with Sheryl Lowenhar, founder of 17 Branches, to talk about the Syn-One Test.
Parkinson’s disease is caused by the accumulation of alpha-synuclein, a misfolded protein that interferes with the brain’s ability to produce dopamine.
UCB presented data from a Phase 1b study of UCB0599, an oral compound that suppresses alpha-synuclein misfolding, at the American Association of Neurology meeting in April.
Dr. Timothy Prestley, Founder & Director of Novus Neurology & TMS in Tuscaloosa, Alabama, was interviewed this week live on ABC’s Talk of Alabama morning show.